Announcements Trials

Browse Landscape Eligibility

Clinical Trials

0 trials

Recent Start date Enrollment

Has results × Hemorrhagic Disorders × Erlotinib Hydrochloride × Clear all

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 122 Lung Neoplasms 46 Pancreatic Neoplasms 29 Non-Squamous Non-Small Cell Lung Cancer 15 Neoplasms 15 Glioblastoma 12 Gliosarcoma 11 Breast Neoplasms 11 Adenocarcinoma of Lung 11 Brain Neoplasms 10 Neoplasm Metastasis 9 Head and Neck Neoplasms 9 Carcinoma, Renal Cell 7 Carcinoma, Hepatocellular 7 Carcinoma, Squamous Cell 6 Astrocytoma 6 Adenocarcinoma, Bronchiolo-Alveolar 6 Squamous Cell Carcinoma of Head and Neck 5 Oligodendroglioma 5 Urinary Bladder Neoplasms 4 Glioma 4 Esophageal Neoplasms 4 Colorectal Neoplasms 4 Carcinoma 4 Adenocarcinoma 4 Recurrence 3 Rectal Neoplasms 3 Ovarian Neoplasms 3 Liver Neoplasms 3 Kidney Neoplasms 3

Interventions

sonidegib 1 ruxolitinib 1 Vorinostat 1 Bortezomib 1 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

No trials found.

Data powered by HemOnc (CC BY 4.0) Colophon ⚡